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Abstract
The importance of neovascularization for primary and metastatic tumor growth fostered numerous clinical trials of
angiogenesis inhibitors either alone or in combination with conventional antineoplastic therapies. One challenge with the
use of molecularly targeted agents has been the disconnection between size reduction and tumor biologic behavior, either
when the drug is efficacious or when tumor resistance emerges. Here, we report the synthesis and characterization of 64Cu-
NOTA-bevacizumab as a PET imaging agent for imaging intratumoral VEGF content in vivo. 64Cu-NOTA-bevacizumab avidly
accumulated in 786-O renal carcinoma xenografts with lower levels in host organs. RAD001 (everolimus) markedly
attenuated 64Cu-NOTA-bevacizumab accumulation within 786-O renal carcinoma xenografts. Tumor tissue and cellular
molecular analysis validated PET imaging, demonstrating decreases in total and secreted VEGF content and VEGFR2
activation. Notably, 64Cu-NOTA-bevacizumab PET imaging was concordant with the growth arrest of RAD001 tumors. These
data suggest that immunoPET targeting of angiogenic factors such as VEGF could be a new class of surrogate markers
complementing the RECIST criteria in patients receiving molecularly targeted therapies.
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Introduction
Angiogenesis, the growth of new blood vessels, is a hallmark of
cancer promoting tumor growth, invasion, and metastasis [1].
Nascent tumors are supported by oxygen and nutrients from
nearby blood vessels, however, as the tumor grows, the blood
supply becomes insufficient and several signaling pathways
stimulate neovascularization expansion [2]. Neovessels may also
act as tumor metastatic conduits [2]. The apparent importance of
neovascularization for primary and metastatic tumor growth
fostered numerous angiogenesis inhibitor clinical trials either alone
or in combination with conventional antineoplastic therapies [3,4].
These agents delayed tumor growth with initial improvements in
therapeutic efficacy associated with vascular network normaliza-
tion [4]. However, not all patients respond to anti-angiogenic
therapy, and resistance almost invariably develops despite initial
improvement. Preclinical studies have suggested that angiogenesis
inhibitors increase tumor invasiveness and metastasis [5], though
this clinical aggressiveness enhancement has yet to be clearly seen
in patients. As such, a better understanding of the limitations and
acquired resistance to angiogenesis inhibitors is necessary. Testing
therapy-induced angiogenic factor secretion reduction offers the
promise of early identification of responsive patients, and more
rapid detection of agent-specific resistance emergence.
Vascular Endothelial Growth Factor (VEGF) plays a central
role in angiogenesis and has emerged as a prominent therapeutic
target. VEGF expression is induced in malignancies by several
mechanisms. At the transcription level, VEGF is a major target of
the heterodimeric hypoxia-inducible factors (HIFs) [6]. HIFs are
composed of, unstable alpha (HIF-1a, HIF-2a, HIF-3a) and
constitutively expressed beta (HIF-1b) subunits [6]. In normoxia,
prolyl and asparaginyl hydroxylases create binding sites for the E3
ubiquitin ligase von Hippel Lindau (VHL) protein and inhibit HIF
transcriptional activity, respectively. During hypoxia, the oxygen-
dependent hydroxylases are inhibited, HIF1/2 transcription
factors are stabilized, and angiogenic, metabolic, and stem cell
target genes are induced. In addition to VEGF, HIF transcription
factors upregulate multiple angiogenic factors [7]. However,
recent data in a nondisease model of HIF-1 gain of function
demonstrates that VEGF is the most important for neovascular
induction [8]. As loss of VHL function underlies clear cell renal
carcinoma development [9], these tumors are particularly
hypervascular due to HIFa-mediated induction of multiple
angiogenic factors including VEGF [6].
In addition to transcription factor overexpression, the phos-
phoinositide 3-kinase (PI3K) pathway is a parallel module
regulating HIF- and VEGF-dependent tumor cell angiogenic
factor production [10]. The PI3K pathway is hyperactivated in the
majority of human cancers due to multiple mechanisms [11].
Mammalian target of rapamycin (mTOR) is a serine-threonine
kinase downstream of PI3K. mTOR resides within two complexes
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localized in distinct intracellular compartments and each posses-
sing specific functions [12,13]. mTORC1 regulates protein
synthesis at multiple levels including translational initiation and
ribosome biogenesis [14]. The HIFa subunits and VEGF are
mTORC1 translational targets, and are functional in normoxic
malignant cells with PI3K activation [15]. mTORC2 modulates
multiple cellular and secondary microenvironmental functions
including cell survival, motility, proliferation, and angiogenesis via
its targets AKT, SGK, and PKC, and HIF-2a. As PI3K and
mTOR are also downstream of VEGFR2, the principal VEGF
receptor signaling in endothelial cells [16], mTOR has a potential
dual neovascularization function in both tumor and endothelial
cells.
Due to its near ubiquitous upregulation, there has been intense
clinical interest in mTOR pathway targeting in solid malignancies.
Rapamycin and its analogs, everolimus, temserolimus, and
deforlimus, (rapalogs), bind to the cyclophilin, FKBP-12, forming
a complex inhibiting mTORC1 [17]. mTORC2 activity is
inhibited with prolonged rapalog exposure in some cell lines
[18], likely due to newly synthesized mTOR sequestration in
inactive rapalog complexes. In early preclinical studies, rapamycin
was shown to decrease both tumor growth and neovascularization
[19]. In other preclinical studies, everolimus inhibited tumor
growth and VEGF expression [17]. Due to promising Phase III
efficacy data, rapalogs have been approved for treatment of
patients with metastatic renal cell cancer (RCC) [20]. However,
therapeutic resistance either is present at the onset or also develops
during rapalog treatment [21]. Several recent and past publica-
tions have highlighted either bypass signaling, or genetic gain of
function of mTOR downstream targets [22–24].
As VEGF is a downstream mTOR activation marker and
a major driver of angiogenesis, its expression level might qualify as
a rapalog sensitivity marker. Bevacizumab is a humanized mono-
clonal antibody that binds to all VEGF isoforms [25]. Previous
studies have suggested that radiolabeled bevacizumab can
noninvasively image and quantify VEGF expression [26–28].
Although 64Cu-DOTA(1,4,7,10 tetraazacyclododecane-1,4,7,10-
tetraacetic acid)-bevacizumab showed promising results for pre-
clinical VEGF xenograft imaging [28], enhanced liver accumula-
tion associated with the known in vivo instability of copper-
DOTA, motivated us to investigate a more stable copper chelate.
Recent work by Zhang et al. using NOTA(1,4,7,10 tetraazacyclo-
noane-N,N’,N’’,-triacetic acid) as a chelate for 64Cu-bevacizumab
illustrated the superiority of this complex for PET imaging [29].
Here we used and evaluated the VEGF specific PET tracer 64Cu-
NOTA-bevacizumab to monitor changes to rapalog administra-
tion. We first tested the imaging efficacy of 64Cu-NOTA-
bevacizumab in renal carcinoma xenografts, a tumor with marked
VEGF overexpression. Next, we tested 64Cu-NOTA-bevacizumab
as an mTOR inhibition tumor response indicator. Our study
demonstrates that this antibody-conjugated PET tracer may
ultimately be useful both to select and continue patients on
molecular therapies targeting secreted angiogenic growth factors.
Materials and Methods
Synthesis of 64Cu-NOTA-bevacizumab
64Cu was produced via the 64Ni(p,n)64Cu nuclear reaction using
the CS-15 cyclotron (Cyclotron Corporation, Berkeley, CA) and
separated via ion exchange as previously described [30].
Bevacizumab (AvastinTM, Genentech/Roche, South San Fran-
cisco, CA) was incubated in a 1:5 molar ratio with 2-
(pisothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic ac-
id (SCN-Bz-NOTA) (Macrocyclics, Dallas, TX) in 0.1 M
NaHCO3 buffer pH 9.0 for 30 min. The resulting product,
NOTA-bevacizumab, was purified via Zeba Spin Desalting
Columns (Pierce Biotechnology, Rockford, IL). 64Cu was com-
plexed with NOTA-bevacizumab at a ratio of 666 MBq/mg
(18 mCi/mg) of antibody in 0.1 M NH4OAc buffer pH 5.5 at
37uC for 1h with constant agitation. 64Cu-NOTA-bevacizumab
was purified using Zeba Spin Desalting Columns (Pierce Bio-
technology, Rockford, IL) and radiochemical purity was de-
termined by analytical size-exclusion chromatography (Superose
12 10/300 GL, GE Healthcare, Piscataway, NJ) with 20 mM
HEPES and 150 mM NaCl (pH 7.3) eluted at a flow rate of
0.75 mL/min. Millenium 32 software (Waters, Milford, MA) was
used to quantify chromatograms by integration. 64Cu-NOTA-
bevacizumab was incubated at 37uC with human serum for 48
hours and evaluated for stability with size-exclusion chromatog-
raphy.
Radiotracer Binding Kinetics
VEGF165 (R&D Systems, Minneapolis, MN) was serially diluted
in 0.5-fold concentrations ranging from 10 mg/mL to 0.4 mg/mL
in bicarbonate coating buffer (5 mM Na2CO3, 35 mM NaHCO3,
pH 9.6). 50 ml of VEGF solution at each concentration was
pipetted in triplicate to the wells of a 96-well plate and incubated
overnight at 4uC. The plate was washed 3 times with 200 ml PBS
followed by the addition of 100 ml of 1% BSA (Sigma, St. Louis,
MO) in PBS to block the remaining protein-binding sites in each
well. After overnight incubation at 4uC, each well was washed 4
times with 200 ml PBS. 74 kBq/0.1 mg (2 mCi) of 64Cu-NOTA-
bevacizumab in 100 ml of PBS was added to each well and
incubated at room temperature for 2 hours. Unbound 64Cu-
NOTA-bevacizumab was carefully removed, each well was
washed 3 times with 200 ml PBS +0.1% Tween 80 (Sigma, St.
Louis, MO), then 200 ml of 0.2 N NaOH solution was added to
each well and incubated for 15 minutes. Radioactivity was
collected for each well and counted on a gamma counter.
Tumor Xenograft Model
786-O (CRL-1932, ATCC, Manassas, VA) renal cell carcinoma
cells were grown in RPMI media supplemented with 10% fetal
bovine serum, and 1% penicillin/streptomycin. Log phase cells
were harvested, resuspended in media at 16105/ml, and 16106
cells were injected subcutaneously into the ears of 6–8 week old
athymic NCr-nu/nu mice (NCI, Frederick, MD). Tumors were
imaged 3 weeks following injection at a tumor size of 94.9 mm3
(n= 4 mice per group). All animal experiments were conducted in
accordance with the NIH Guidelines for the Care and Use of
Research Animals and with approval of Washington University’s
Animal Studies Committee.
Radiotracer Biodistribution Studies
In vivo biodistribution studies were performed with athymic
nude mice (n = 4 mice) to determine the uptake of 64Cu-NOTA-
bevacizumab in 786-O renal cell cancer xenografts in relation
to normal organs. 64Cu-bevacizumab, 0.555 MBq/
0.83 mg,15 mCi, was injected i.v., mice sacrificed 24 hours
later, and specific uptake of tumors and select organs was
measured using a gamma counter with background and decay
correction. Specific uptake was expressed as % injected dose per
gram of tissue (%ID/g) as calculated by normalization to the
total activity injected, using a known amount of injected activity
as a standard.
64Cu-Bevacizumab ImmunoPET
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Small Animal PET Studies
Small animal PET/CT experiments were performed with the
Inveon MicroPET/CT scanner (Siemens, Knoxville, TN). 64Cu-
bevacizumab (2.96–3.7 MBq/4.4–5.5 mg (80–100 mCi) in 100 mL
0.9% sterile saline) was injected i.v. Twenty four hours later, mice
were anesthetized with 2% isoflurane and imaged. Twenty minute
static images (n = 4 mice for each treatment group) were collected
and co-registered with image display software (Inveon Research
Workplace, Siemens, Knoxville, TN). Regions of interest including
the tumor and muscle were contoured, and the standard uptake
values (SUV) for tumors were determined using the formula:
SUV= [(MBq/mL)6(animal wt. (g))/injected dose (MBq)].
RAD001 Treatment
RAD001 (Everolimus) emulsion (Novartis, San Diego, CA) was
administered by daily gavage at 10 mg/kg of body weight. Control
animals received a placebo emulsion (Novartis proprietary
formulation). After the initial imaging experiments described
above, mice were administered RAD001 or vehicle for 7
consecutive days and subsequently re-imaged with 64Cu-NOTA-
bevacizumab (2.96–3.7 MBq/4.4–5.5 mg) as described above
(RAD001, n = 4, vehicle, n = 4 mice). Biodistribution studies (as
described above) were performed after completion of the small
animal PET imaging on Day 7. For tumor growth experiments,
a separate cohort of 8–12 week old mice bearing bilateral ear
tumors were treated with vehicle (n = 7 mice, 14 tumors analyzed)
or RAD001 (n= 9 mice, 18 tumors). Ear tumor growth was
determined by measurement of the three greatest perpendicular
dimensions and the tumor volume in mm3 was analyzed for each
tumor on days 7 and 14 of treatment.
Immunoblotting
RAD001 (n= 3 mice) and vehicle control (n = 3 mice) 786-O
ear tumors were harvested, homogenized in RIPA buffer (50 mM
Tris at pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% nonylphenyl-
polyethylene glycol (Nonidet P-40 substitute), 0.1% SDS, 1%
sodium deoxycholate, 1% Triton X-100) supplemented with
Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktails
1 and 2 (all 1:50; Sigma-Aldrich, St. Louis, MO). Cleared tumor
lysates were quantified for protein concentration using the BCA
assay kit (Pierce Biotechnology, Rockford, IL) and stored at
280uC. Total protein (120 mg) was separated on SDS poly-
acrylamide gels, transferred to PVDF membranes (Invitrogen,
Carlsbad, CA), blocked with 10% non-fat dry milk in Tris-
buffered saline (pH 7.6) containing 0.5% Tween 20 (TBST), and
probed with rabbit antibodies for S6KT389, S6K, AKTS473, AKT,
pVEGFR2Y1175, VEGFR2 (all 1:1,000, Cell Signaling Technol-
ogy), chicken polyclonal VEGF antibody (1:2,500 Ab14078,
Abcam), and rabbit polyclonal for b-tubulin (1:35,000, Abcam).
After overnight incubation at 4uC, membranes were washed three
times in TBST, incubated for 1 hour at room temperature in
horseradish peroxidase-linked secondary antibodies (1:5,000,
Santa Cruz Biotechnology, Santa Cruz, CA), and protein bands
were visualized with ECL plus reagent (GE Healthcare, Piscat-
away, NJ). Protein loading was normalized to b-tubulin.
VEGF ELISA
786-O cells were seeded into 6-well plates at a cell density of
36105 cells per well and cultivated in complete medium overnight.
Log-phase cells were then cultured in serum-free RPMI 1640
medium supplemented with vehicle (DMSO) or 100 nM or
1,000 nM rapamycin for 6 hours, the medium was replaced by
2 ml of fresh serum-free medium containing vehicle or the same
different rapamycin concentrations, and the cell culture superna-
tant was harvested 18 hr later. Secreted VEGF protein in
conditioned medium were quantified by ELISA in four in-
dependent cultures per group using the Human VEGF Quantikine
ELISA Kit (R&D, Minneapolis, MN) and normalized to total
cellular DNA content.
Statistical Analysis
Data are presented as mean 6 SD. The two-tailed Student’s t-
test, the Mann-Whitney U test, one- and two-way ANOVA, and
linear regression analysis (GraphPad Prism 6.0b, La Jolla, CA)
were used for significance testing. A p value of ,0.05 was
considered statistically significant.
Results
Synthesis and in vitro Determination of 64Cu-NOTA-
Bevacizumab VEGF Binding Affinity
As previous studies using 64Cu-DOTA conjugates showed high
liver radioactivity accumulation indicating potential transmetalla-
tion to other proteins in vivo [28,31], we opted to use NOTA
which forms a more stable copper complex [32]. Bevacizumab was
conjugated to NOTA-Bz-NCS and radiolabeled with 64Cu.
Radiolabeling efficiency was 92.1%64.7%, radiochemical purity
was 98.161.7%, and specific activity was approximately
644 MBq/mg (17.4 mCi/mg) (n = 5 independent experiments).
64Cu-NOTA-bevacizumab was stable up to 48 hours in serum at
37uC with no visible degradation products on size-exclusion
HPLC analysis.
To test 64Cu-NOTA-bevacizumab VEGF specificity immuno-
reactivity assays were performed. VEGF165 was plated in triplicate
in incremental concentrations ranging from 0.4 to 10 mg/mL. The
amount of bound 64Cu-NOTA-bevacizumab as a percentage of
total activity added was elevated with increasing concentration
from 13.360.72% at 0.4 mg/mL VEGF165 to 34.463.89% with
10 mg/mL VEGF (Figure 1). Co-incubation with 20 mg excess
unlabeled bevacizumab markedly decreased 64Cu-NOTA-bevaci-
zumab VEGF165 binding to 2.0460.35% demonstrating specific-
ity of radiolabeled antibody immunoreactivity (Figure 1).
Figure 1. 64Cu-NOTA-bevacizumab immunoreactivity. Increased
binding of 64Cu-NOTA-bevacizumab was observed with increasing
concentration of VEGF. The inhibitable binding blockade using 20 mg
unlabeled bevacizumab highlights the tracer specificity. All assays were
conducted in triplicate. Bars shown are +/2 standard deviation.
doi:10.1371/journal.pone.0058949.g001
64Cu-Bevacizumab ImmunoPET
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64Cu-NOTA-Bevacizumab Biodistribution and Imaging
Indicates Enhanced Renal Tumor Localization
To test 64Cu-NOTA-bevacizumab avidity in a tumor with
marked VEGF expression, biodistribution studies were performed
in athymic nude mice bearing 786-O heterotopic ear tumors
Figure 2A and B). The circulating level of 64Cu-bevacizumab in
the blood was 9.363.8% injected dose per gram (ID/g). Tumor
uptake was 22.065.3% ID/g whereas muscle uptake was only
1.160.4% ID/g. Spleen, lung, liver, and kidney uptake were also
low at 5.862.5%, 4.861.7%, 5.661.4%, and 2.660.6%, re-
spectively. Thus even though the mice bore two tumors, one on
each ear, uptake in the single ear tumor sampled was significantly
robust compared to host organs. Addition of a 100 mg blocking
dose of unlabeled bevacizumab significantly inhibited tumor 64Cu-
NOTA-bevacizumab uptake demonstrating radiotracer specificity
in vivo (Figure 2A). Small animal PET imaging demonstrated high
tumor uptake of 64Cu-NOTA-bevacizumab (SUV 10.6)
(Figure 2B). As a further test of specificity, we administered a 10-
fold excess iv blocking dose of bevacizumab in conjunction with
the 64Cu-NOTA-bevacizumab PET tracer. The unlabeled block-
ing dose diminished tumor tissue uptake three-fold (Figure 2B).
Remarkably, the blocking dose abrogated tumor image detection
(6.362.1%), with residual signal emanating from the blood tracer
pool (Figure 2B).
RAD001 Diminishes Renal Tumor Target Phosphorylation
and VEGF Content
Prior to testing 64Cu-NOTA-bevacizumab PET therapeutic
response imaging, a cohort of mice was treated daily with
RAD001, 10 mg/kg, or vehicle, to determine the rapalog’s effect
on tumor mTOR signaling and VEGF content. Fourteen days of
RAD001 produced undetectable phosphorylation of the mTOR
specific threonine 389 site of ribosomal protein S6 kinase
(Figure 3). In contrast to previous work with human cell lines
demonstrating rapalog negative feedback PI3K-mTORC2 in-
duction [33], there was a 15% reduction AKT phosphorylation at
serine 473 (pAKTS473), an mTORC2 target, consistent with
rapalog-mTOR sequestration [34]. RAD001 treatment decreased
tumoral VEGF protein expression by 60% with a concomitant
60% reduction in VEGFR2 phosphorylation, the principle
endothelial cell VEGF signaling receptor as determined by
normalization to the respective tubulin loading controls
(Figure 3A). To test the cell autonomous effects of rapalogs on
786-O VEGF secretion, conditioned media from rapamycin and
vehicle-treated cultures were analyzed for VEGF content.
Rapamycin caused a 20% drop in secreted VEGF compared to
control (Figure 3B). This partial response of 786-O cells could be
due to inability of rapamycin to inhibit key mTORC1 targets
regulating translation of ‘‘weak mRNAs’’, such as 4E-BP1 [13]
(Figure 3). There are several explanations for the more pro-
nounced decrease in VEGF levels in the immunoblots versus
ELISA analysis. As ELISA measured secreted VEGF it is possible
that VEGF was secreted and prior to initiation of rapamycin
treatment, therefore the drug only inhibited the translation and
secretion of newly synthesized growth factor in cultured cells. In
addition, rapamycin may effect the cellular VEGF secretion
pathway in a distinct mechanism compared with VEGF mRNA
translational regulation. More likely, was the pronounced differ-
ence between cell culture wherein nutrient provision is uniform,
despite serum starvation, versus the tumor microenvironment in
intact mice potentially possessing perfusion mismatches or
arteriovenous shunting.
64Cu-NOTA-Bevacizumab Biodistibution Alterations in
Response to RAD001
Next, we investigated whether 64Cu-NOTA-bevacizumab PET
imaging could detect RAD001-mediated tumoral VEGF content
decreases in a mouse model of RCC. Biodistribution studies were
performed at 7 rather than 14 days of RAD001 administration to
test whether VEGF uptake was dissociated from significant
alterations of tumor growth (Figure 4A). RAD001 significantly
decreased tumor 64Cu-NOTA-bevacizumab uptake two-fold,
vehicle treated tumors, 30.368.3%, RAD001 13.862.6% ID/g
respectively, p,0.001. MicroPET/CT imaging studies performed
in a parallel cohort of tumor bearing mice (Figure 4B and C)
Figure 2. 64Cu-NOTA-bevacizumab biodistribution. (A) Mice with 786-O renal cell carcinoma ear tumors were i.v. injected with 100 mCi of
64Cu-NOTA-bevacizumab (n = 4 mice). 24 hours post injection select organs and tumors were collected, weighed, and the amount of activity in each
tissue was assessed in a gamma-counter. The decay-corrected % injected dose (ID)/g tissue was calculated for each organ. A blocking dose of 100 mg
unlabeled bevacizumab markedly and specifically reduced tumor tracer uptake with no detectable effect on host organ tracer accumulation. (B) Mice
with 786-O renal cell carcinoma ear tumors were administered 100 mCi of 64Cu-NOTA-bevacizumab i.v. in the absence (left panel), or presence (right
panel), of 100 mg unlabeled antibody. Twenty min static scans were acquired 24 hr post-injection.
doi:10.1371/journal.pone.0058949.g002
64Cu-Bevacizumab ImmunoPET
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revealed a three-fold diminution of tumoral 64Cu-NOTA-
bevacizumab signal intensity, SUV 4.0, compared vehicle-treated
mice, SUV 12.2. Tumor growth response analysis in another
parallel cohort of RAD001 and vehicle treated mice (see Materials
and Methods) revealed that RAD001 prevented tumor size
expansion during the 14 days of treatment as determined by
linear regression analysis wherein the slope of the vehicle group
growth increase was 14.98 (p= 0.0001), whereas the slope of the
RAD001 treated group was 0.20 (p= 0.92). Two-way ANOVA
analysis also revealed a significant difference in tumor sizes
according to measurement day and vehicle versus drug treatment.
Unfortunately, differential, RAD001 tumor volume diminution
had already reached statistical significance by day 7, as determined
by one-way ANOVA, p= 0.003 for the day 0-day 7 interval or
single time point analysis of day 7 tumor size between the vehicle
and RAD001 groups, Mann-Whitney U-test, p = 0.013, prevent-
ing determination of the predictive value of VEGF-PET imaging
at this time point (Figure 5).
Discussion
In this study, we successfully synthesized and evaluated 64Cu-
NOTA-bevacizumab for imaging of VEGF levels in RCC tumor
xenografts. This compound was stable, specifically accumulated in
tumors, and could be blocked by the addition of unlabeled
bevacizumab. Additionally, a RAD001-mediated decrease in
VEGF expression was clearly visualized by PET imaging using
64Cu-NOTA-bevacizumab. Tracer uptake diminution was con-
comitant with static effect of RAD001 on tumor growth. Thus,
64Cu-NOTA-bevacizumab may be a novel surrogate biomarker
for disease stabilization mediated by rapalog or mTOR kinase
inhibitor therapies.
Traditionally solid tumor therapeutic response is scored based
on tumor dimensional reduction, either measured physically,
radiographically, or by CT and MRI. The Response Evaluation
Criteria in Solid Tumors (RECIST) and its more recent
RECIST1.1 version provides a standardized methodology for
efficacy comparisons across drugs and studies. However, the
emergence of molecularly targeted therapies challenges RECIST
as an efficacy benchmark [35]. When molecularly targeted
therapies are effective, they principally produce stable disease
(SD) or partial response (PR) with minimal changes in tumor size.
Limitations of RECIST for molecular therapy efficacy determi-
nation motivates development of CT, MRI, and ultrasound
imaging algorithms and techniques tailored in particular for tumor
vascular targeting drugs. These algorithms are designed to detect
changes in overall tumor vascular density, angiogenic factor
mediated vascular leakage, and tumor vascular flow [36].
Another approach to assess therapy efficacy is PET. Tumors are
characterized by enhanced glucose and thymidine uptake in
response to genetic dysregulation of metabolism and proliferation
[37]. The radiotracers 18F-fluorodeoxyglucose (FDG) and 18F-
fluorothymidine (FLT) [38–40], image tumor glucose uptake and
DNA synthesis detecting primary tumor and metastasis and
monitoring therapeutic response. Both FDG and FLT PET can
reveal therapeutic efficacy prior to tumor volume changes. These
two PET tracers are challenged by the fact that some cancers such
as RCC (and prostate) are predominantly FDG insensitive [41],
and FLT underestimates proliferation in tumors with activated
pyrimidine de-novo synthesis or salvage pathway upregulation
[42]. However, in the minority of FDG positive RCCs, PET
Figure 3. mTORC1 signaling and VEGF secretion in response to RAD001. (A) RAD001 abrogated mTORC1-mediated ribosomal protein S6
kinase phosphorylation in tumor lysates without affecting mTORC1-mediated 4E-BP1 phosphorylation. Tumoral VEGF content was decreased by 60%
and accompanied by a commensurate similar decrease in VEGFR2 phosphorylation. The immunoblot data were normalized to the unphosphorylated
total protein for each target and to b-tubulin. Each lane is lysate from one tumor on one mouse. (B) ELISA analysis of conditioned media from RAD001
treated 786-O cultured cells, n = four independent cultures per treatment group, demonstrated a 20% drop in secreted VEGF protein level. The ELISA
data were normalized to total cellular DNA to correct for RAD001-mediated decreases in total cell protein. *p,0.0001.
doi:10.1371/journal.pone.0058949.g003
64Cu-Bevacizumab ImmunoPET
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detects tumor response earlier than size reduction and predicts
better progression free survival (PFS) [14].
Despite limitations in cancers such as RCC, a new dimension in
PET has become apparent in the last few years. ‘‘ImmunoPET’’
tracers are antibody-radionuclide conjugates binding to proteins
either attached to the cell surface, or secreted into the tumor
microenvironment [43]. Using bifunctional chelators such as the
NCS (isothiocyanate) or NHS (N-Hydroxysuccinimide) forms of
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
or 1,4,7-triazacyclononane-N,N’N’’-triacetic acid (NOTA), radio-
nuclide metal ions can be complexed in the chelator cores while
covalent bonds are formed with free lysine groups on antibodies or
peptides [44]. The power of this approach is that DOTA/NOTA
chelated PET tracers can be conjugated to antibodies specific for
a repertoire of angiogenic factors. As VEGF is the principal
angiogenic factor produced by RCC (and most other cancers as
well), this angiogenic factor has been explored as an imaging
target. Prior studies have evaluated the use of radiolabeled
bevacizumab for PET imaging of VEGF expression. For example,
bevacizumab has been radiolabeled with 89Zr [26] and 86Y [27]
for preclinical imaging of ovarian xenograft models. Despite the
ability of these agents to image VEGF, the high energy and
abundance of the gamma decay from these radionuclides are an
exposure concern compared to 64Cu which has a much lower high
Figure 4. Pre and post-treatment microPET/CT Study. (A) Biodistribution of 64Cu-NOTA-bevacizumab in mice (n = 4 mice per group) bearing
786-O renal cell carcinoma tumors after treatment with RAD001 or vehicle. (B) Mice bearing 786-O renal cell carcinoma ear tumors were scanned at
baseline following i.v. injection of 100 mCi 64Cu-NOTA-bevacizumab (n = 4). RAD001 was then administered for 7 days and the scans repeated. There
was a marked decreased in 64Cu-NOTA-bevacizumab signal in the RAD001 compared to the vehicle control treated mouse. (C) Diminution of
standard uptake value (SUV) in the RAD001 compared to vehicle treated mice.
doi:10.1371/journal.pone.0058949.g004
Figure 5. RAD001-mediated 786-O growth inhibition. Tridimen-
sional ear tumor growth determination reveals that RAD001 (&)
essentially prevents the growth of ear tumors (n = 9 mice bearing 18
bilateral tumors) compared to linear growth in vehicle controls (N)
(n = 7 mice bearing 14 bilateral tumors).
doi:10.1371/journal.pone.0058949.g005
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energy gamma decay abundance. Paudyal et al. evaluated 64Cu-
DOTA- bevacizumab for preclinical VEGF expression imaging in
colorectal xenografts [28]. Liver uptake was relatively high,17.2%
ID/g, in contrast to our 64Cu-NOTA-bevacizumab tracer where it
was 4.8% ID/g. An explanation for the differential liver uptake
could be the higher 64Cu binding affinity of NOTA compared to
DOTA. Nagengast et al. demonstrated the ability of 89Zr-
radiolabeled ranibizumab to measure dynamic changes in VEGF
expression following sunitinib treatment, a multi-tyrosine kinase
inhibitor also used in metastatic renal cancer [26]. However, low
tumor (,5–6% ID/g) and high kidney uptake [26] may limit the
use of radiolabeled ranibizumab in intra-abdominal tumors. In
contrast, we found relatively high 64Cu-NOTA-bevacizumab
accumulation (,30% ID/g) in untreated renal cancer xenografts
tumors in comparison to normal organs such as liver, kidney, GI
tract, and bladder, similar to other groups using this tracer [29].
Our increased VEGF signal-to-noise facilitated tumor imaging
enhancement and its rapalog-mediated decrease.
A potential limitation of our study is that bevacizumab binds
only to human and not to mouse VEGF. As such, host-derived
VEGF sources such as stromal fibroblasts, myeloid cells, and
vascular supporting cells were undetectable [45–47]. Therefore, in
humans, the potential exists for increased tumor to background
ratio of 64Cu-NOTA-bevacizumab uptake due to VEGF pro-
duction from multiple sites in the tumor microenvironment.
Moreover, inhibition of VEGF secretion from tumor associated
myeloid cells could be of near equal therapeutic importance as
malignant cellular VEGF production. In addition, the ability of
humanized bevacizumab to detect VEGF in the heart, lung,
kidney, and brain could be important predictors of VEGF
signaling inhibitor toxicities such as proteinuria, pulmonary
hemorrhage, and cardiotoxicity [48,49]. Signal to noise and utility
of VEGF content imaging in normal organs, for therapy toxicity
monitoring will be interesting venues for investigation in patient
studies.
Although rapid tumor growth prevented assessment of the
predictive ability, of 64Cu-NOTA-bevacizumab PET, the concor-
dance of imaging and tracer biodistribution with our preclinical
disease stabilization suggests a translational role for immunoPET
during patient selection for molecularly targeted therapies.
mTORC1 regulation of ‘‘weak’’ mRNA translation encompasses
secreted growth factors many of which are angiogenic factors [50].
Therefore, VEGF, or an expanded repertoire of immunoPET
tracers, cognate for other secreted molecules that are mTOCR1
targets, could detect patients that may be inhibitor sensitive. This
potential ability for rapid patient selection based on functional
PET is particularly important as substantial percentages of solid
tumors either possess signaling pathways bypassing the mTORC1
translational requirement, or upregulate or amplify genes encod-
ing downstream mTORC1 translational effectors [50]. In
addition, breakthrough from mTORC1-mediated stable disease
to progressive disease could also be detected prior to measurable
tumor expansion. Conversely, 64Cu-NOTA-bevacizumab PET
could also be used to track elevations of tumor VEGF during
VEGFR inhibitor therapies. Drug dosage could then be increased
in those patients to match the increase in tumor production. In
addition, libraries of immunoPET tracers could potentially
pinpoint which compensatory angiogenic factor(s) are induced
during mTORC1 or VEGFR inhibitor therapies and an
appropriate alternative pathway-specific inhibitor deployed. As
such, the concept of immunoPET reporting on tumor angiogenic
factor, chemokine, or cytokine production offers great potential for
therapy tailored personalized medicine. However, in order to
supplant or even augment criteria such as RECIST that was
established from data acquired for large patient populations, PET
studies will similarly need to be tested in large patient cohorts
preferably encompassing several different tumor histotypes.
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